Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
511 results
Annals of palliative medicine, Volume 8, Issue 2, 1 1 2019, Pages 207-209 Brain metastases: costs for care need to be spend more effectively! Postmus PE
Cited 3 times since 2018 (0.6 per year) source: EuropePMC
Cancer, Volume 124, Issue 24, 1 1 2018, Pages 4667-4675 ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). Morgensztern D, Cobo M, Ponce Aix S, Postmus PE, Lewanski CR, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Fasola G, Ardizzoni A, Bhore R, Wolfsteiner M, Talbot DC, Jin Ong T, Govindan R, On Behalf Of The Abound L Investigators
Background: This randomized phase 2 trial compared the efficacy and safety of second-line nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with or without the addition of CC-486 (an oral formulation of 5-azacytidine) in patients with advanced-stage, nonsquamous non-small cell lung cancer. Methods: Patients were randomized to receive either nab-paclitaxel 100 mg/m2 on days 8 and 15 plus CC-486 200 mg daily on days 1 to 14 or single-agent nab-paclitaxel 100 mg/m2 on days 1 and 8, with both r... Abstract
Cited 11 times since 2018 (1.9 per year) source: EuropePMC
OncoTargets and therapy, Volume 11, 6 1 2018, Pages 4573-4582 Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study. Reck M, Mellemgaard A, Novello S, Postmus PE, Gaschler-Markefski B, Kaiser R, Buchner H
Background: Nintedanib in combination with docetaxel is approved in the European Union and other countries for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) of adenocarcinoma histology after first-line chemotherapy, based on the overall survival findings of Phase III LUME-Lung 1 study. Change in target lesion size over time as a treatment effect was assessed in patients from this study. Methods: Tumor size was evaluated using predefined tumor measurements. Mixed-effe... Abstract
Cited 16 times since 2018 (2.8 per year) source: EuropePMC
Future oncology (London, England), Volume 14, Issue 23, 6 1 2018, Pages 2415-2431 Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. Califano R, Lal R, Lewanski C, Nicolson MC, Ottensmeier CH, Popat S, Hodgson M, Postmus PE
Immune checkpoint inhibitors targeting PD-1 or PD-L1 represent a standard treatment option for patients with advanced non-small-cell lung cancer. However, a substantial proportion of patients will not benefit from these treatments, and robust biomarkers are required to help clinicians select patients who are most likely to benefit. Here, we discuss the available evidence on the utility of clinical characteristics in the selection of patients with advanced non-small-cell lung cancer as potential... Abstract
Cited 4 times since 2018 (0.7 per year) source: EuropePMC
Drug design, development and therapy, Volume 12, 24 4 2018, Pages 1445-1451 nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial. Gridelli C, Chen T, Ko A, O'Brien ME, Ong TJ, Socinski MA, Postmus PE
Background: Limited data on elderly patients with squamous advanced non-small cell lung cancer (NSCLC) preclude optimal treatment. Here, we report the outcomes of a retrospective analysis of a subset of patients ≥70 years with squamous histology from the Phase III trial that evaluated nab-paclitaxel/carboplatin vs paclitaxel/carboplatin. Patients and methods: Patients with stage IIIB/IV NSCLC received (1:1) nab-paclitaxel 100 mg/m2 on days 1, 8, and 15 or paclitaxel 200 mg/m2 on day 1, both with... Abstract
Cited 2 times since 2017 (0.3 per year) source: EuropePMC
Lung cancer (Amsterdam, Netherlands), Volume 117, 11 2 2017, Pages 62-63 Changing health care costs for NSCLC, what does it mean? Postmus PE
Cited 1 times since 2017 (0.2 per year) source: EuropePMC
Journal of thoracic disease, Volume 9, Issue 10, 1 1 2017, Pages 3572-3575 Prophylactic cranial irradiation for stage IV small cell lung cancer, live longer or reduce morbidity of brain metastases? Postmus PE, Smit EF
Cited 195 times since 2017 (29.6 per year) source: EuropePMC
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 35, Issue 30, 30 5 2017, Pages 3449-3457 Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O'Byrne K, Kopit J, Li M, Tschaika M, Reck M
Purpose Patients with squamous non-small-cell lung cancer (NSCLC) have poor prognosis and limited treatment options. This randomized, double-blind, phase III study investigated the efficacy and safety of first-line ipilimumab or placebo plus paclitaxel and carboplatin in advanced squamous NSCLC. Patients and Methods Patients with stage IV or recurrent chemotherapy-naïve squamous NSCLC were randomly assigned (1:1) to receive paclitaxel and carboplatin plus blinded ipilimumab 10 mg/kg or placebo e... Abstract
Cited 717 times since 2017 (106.3 per year) source: EuropePMC
Annals of oncology : official journal of the European Society for Medical Oncology, Volume 28, Issue suppl_4, 1 1 2017, Pages iv1-iv21 Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S, ESMO Guidelines Committee
Cited 32 times since 2016 (4.4 per year) source: EuropePMC
British journal of cancer, Volume 115, Issue 12, 22 4 2016, Pages 1504-1512 Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Kuiper JL, Hashemi SM, Thunnissen E, Snijders PJ, Grünberg K, Bloemena E, Sie D, Postmus PE, Heideman DA, Smit EF
Background: Data on non-small-cell lung cancer (NSCLC) patients with non-classic epidermal growth factor receptor (EGFR) mutations are scarce, especially in non-Asian populations. The purpose of this study was to evaluate prevalence, clinical characteristics and outcome on EGFR-TKI treatment according to type of EGFR mutation in a Dutch cohort of NSCLC patients. Methods: We retrospectively evaluated a cohort of 240 EGFR-mutated NSCLC patients. Data on demographics, clinical and tumour-related fe... Abstract
Cited 23 times since 2016 (3 per year) source: EuropePMC
SpringerPlus, Volume 5, Issue 1, 7 1 2016, Pages 1506 Risk of spontaneous pneumothorax due to air travel and diving in patients with Birt-Hogg-Dubé syndrome. Johannesma PC, van de Beek I, van der Wel JW, Paul MA, Houweling AC, Jonker MA, van Waesberghe JH, Reinhard R, Starink TM, van Moorselaar RJ, Menko FH, Postmus PE
Background and objectives: Birt-Hogg-Dubé syndrome is an autosomal dominant disorder characterized by skin fibrofolliculomas, lung cysts, spontaneous pneumothorax and renal cell cancer due to germline folliculin (FLCN) mutations (Menko et al. in Lancet Oncol 10(12):1199-1206, 2009). The aim of this study was to evaluate the incidence of spontaneous pneumothorax in patients with BHD during or shortly after air travel and diving. Methods: A questionnaire was sent to a cohort of 190 BHD patients an... Abstract
Cited 2 times since 2016 (0.3 per year) source: EuropePMC
Familial cancer, Volume 15, Issue 2, 1 1 2016, Pages 297-300 Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis? Johannesma PC, Houweling AC, Menko FH, van de Beek I, Reinhard R, Gille JJ, van Waesberghe JT, Thunnissen E, Starink TM, Postmus PE, van Moorselaar RJ
Renal cell cancer (RCC) represents 2-3% of all cancers and is the most lethal of the urologic malignancies, in a minority of cases caused by a genetic predisposition. Birt-Hogg-Dubé syndrome (BHD) is one of the hereditary renal cancer syndromes. As the histological subtype and clinical presentation in BHD are highly variable, this syndrome is easily missed. Lung cysts--mainly under the main carina--are reported to be present in over 90% of all BHD patients and might be an important clue in diffe... Abstract
Cited 19 times since 2015 (2.3 per year) source: EuropePMC
American journal of respiratory and critical care medicine, Volume 192, Issue 12, 1 1 2015, Pages 1483-1489 Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial Lesions. van Boerdonk RA, Smesseim I, Heideman DA, Coupé VM, Tio D, Grünberg K, Thunnissen E, Snijders PJ, Postmus PE, Smit EF, Daniels JM, Sutedja TG
Rationale: Autofluorescence bronchoscopy (AFB) and computed tomography (CT) enable lung cancer (LC) detection at the early (pre-)invasive stage. However, LC risk in patients with preinvasive endobronchial lesions is unclear. Objectives: To assess LC incidence and identify potential risk determinants in patients with preinvasive lesions. Methods: In our tertiary care referral center, 164 subjects with preinvasive lesions were monitored up to 12.5 years by repeated AFB and CT. Occurrence of LC was... Abstract
Cited 28 times since 2015 (3.3 per year) source: EuropePMC
European journal of cancer (Oxford, England : 1990), Volume 51, Issue 17, 28 4 2015, Pages 2534-2544 Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study. Hendriks LE, Derks JL, Postmus PE, Damhuis RA, Houben RM, Troost EG, Hochstenbag MM, Smit EF, Dingemans AM
Purpose: To analyse the prognostic impact on overall survival (OS) of single versus multiple organ metastases, organ affected, and local disease status in a population based stage IV non-small cell lung cancer (NSCLC) cohort. Methods: In this observational study, data were analysed of all histologically confirmed stage IV NSCLC patients diagnosed between 1 January 2006 and 31 December 2012 registered in the Netherlands Cancer Registry. Location of metastases before treatment was registered. Mult... Abstract
Cited 7 times since 2015 (0.8 per year) source: EuropePMC
Lung cancer (Amsterdam, Netherlands), Volume 89, Issue 1, 20 3 2015, Pages 19-26 Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer? Vincenten JP, Smit EF, Grünberg K, Postmus PE, Snijders PJ, Witte BI, Heideman DA, Thunnissen E
Objectives: Adenocarcinoma (ADC) of the lung may harbor EGFR- or KRAS-mutations, which are relevant for treatment decisions. There is no consensus on the percentages of EGFR- and KRAS-mutations that are allowed to be missed by a diagnostic algorithm, although a percentage of less than 1% for EGFR-mutations has been suggested. The current guidelines do not advise to perform EGFR-mutation analysis in unequivocal squamous cell carcinoma (SqCC). For KRAS-mutations no threshold for missing cases is s... Abstract
Cited 28 times since 2015 (3.1 per year) source: EuropePMC
British journal of cancer, Volume 112, Issue 6, 17 3 2015, Pages 1105-1113 DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approach. Hubers AJ, Heideman DA, Burgers SA, Herder GJ, Sterk PJ, Rhodius RJ, Smit HJ, Krouwels F, Welling A, Witte BI, Duin S, Koning R, Comans EF, Steenbergen RD, Postmus PE, Meijer GA, Snijders PJ, Smit EF, Thunnissen E
Background: Lung cancer has the highest mortality of all cancers. The aim of this study was to examine DNA hypermethylation in sputum and validate its diagnostic accuracy for lung cancer. Methods: DNA hypermethylation of RASSF1A, APC, cytoglobin, 3OST2, PRDM14, FAM19A4 and PHACTR3 was analysed in sputum samples from symptomatic lung cancer patients and controls (learning set: 73 cases, 86 controls; validation set: 159 cases, 154 controls) by quantitative methylation-specific PCR. Three statistic... Abstract
Cited 20 times since 2015 (2.2 per year) source: EuropePMC
Thorax, Volume 70, Issue 5, 16 3 2015, Pages 468-472 Long-term follow-up after first-line bronchoscopic therapy in patients with bronchial carcinoids. Brokx HA, Paul MA, Postmus PE, Sutedja TG
Background: Carcinoid of the lung is considered to be a low-grade malignancy. A subgroup presents as an endobronchial tumour. Surgical resection is considered the standard approach because of its metastatic potential and the possibility of an iceberg phenomenon for the endobronchial subgroup. Advances in non-invasive and minimally invasive technologies seem to justify a more lung parenchyma-sparing approach. Methods: In patients presenting with bronchial carcinoids, initial bronchoscopic treatme... Abstract
Cited 1 times since 2015 (0.1 per year) source: EuropePMC
Personalized medicine, Volume 12, Issue 2, 1 1 2015, Pages 63-66 Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy. Kuiper JL, Bahce I, Voorhoeve C, Yaqub M, Heideman DA, Thunnissen E, Paul MA, Postmus PE, Hendrikse NH, Smit EF
Tumor heterogeneity plays an important role in the development of treatment-resistance, especially in the current era of targeted therapies. Although tumor heterogeneity is a widely recognized phenomenon, it is at present unclear how this knowledge should be incorporated into daily clinical practice. In this report, we describe an innovative nuclear imaging method that may play a role in detecting tumor heterogeneity in the future. Abstract
Cited 34 times since 2014 (3.7 per year) source: EuropePMC
The European respiratory journal, Volume 45, Issue 4, 23 4 2014, Pages 1191-1194 Prevalence of Birt-Hogg-Dubé syndrome in patients with apparently primary spontaneous pneumothorax. Johannesma PC, Reinhard R, Kon Y, Sriram JD, Smit HJ, van Moorselaar RJ, Menko FH, Postmus PE, Amsterdam BHD working group
Journal of thoracic disease, Volume 6, Issue 12, 1 1 2014, Pages E299-300 Pleural fluid is surrogate for time. Postmus PE